Translational Lung Cancer Research

Article	Citations
Contrast-enhanced CT and PET-CT characteristics of primary tracheal lymphoepithelioma-like carcinoma: case series	58
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review	56
Pushing the boundaries of minimally invasive surgery	56
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer	49
Metachronous development of L858R and T790M EGFR mutations following ALK inhibitor therapy in stage IV lung adenocarcinoma: a case report	47
PFKP confers chemoresistance by upregulating ABCC2 transporter in non-small cell lung cancer	45
Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors	44
Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies—a narrative review	39
Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab	38
How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review	34
Microbiota modulate lung squamous cell carcinoma lymph node metastasis through microbiota-geneset correlation network	33
Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer	32
End-to-side anastomosis in complex tracheal resection and reconstruction: a case series study	32
Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report	29
Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy	28
The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–2030	28
Shared decision-making for prophylactic cranial irradiation in extensive-stage small-cell lung cancer: an exploratory study	27
Menstrual factors, reproductive history, and risk of lung cancer: a multi-center population-based cohort study in Chinese females	27
Real-time digital polymerase chain reaction (PCR) as a novel technology improves limit of detection for rare allele assays	27
Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?	25
Predictive value of perioperative carcinoembryonic antigen changes for recurrence in non-small cell lung cancer	25
Discrepancies in PD-L1 expression, lymphocyte infiltration, and tumor mutational burden in non-small cell lung cancer and matched brain metastases	25
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer	25
Development of an AI model for predicting hypoxia status and prognosis in non-small cell lung cancer using multi-modal data	24
Can circulating tumor DNA guide treatment de-escalation in metastatic lung adenocarcinoma harboring actionable genomic alterations?	24

Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung c	23
Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?	22
Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial	22
KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer	22
Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression	21
Dynamic change of CD8+ T cell: immunotherapy fate tell?	21
Real-world data on severe lung cancer: a multicenter retrospective study	21
The opportunities and challenges of perioperative therapy of localized non-small cell lung cancer—thoughts from the KEYNOTE-671 trial	21
Tarlatamab: the promising immunotherapy on its way from the lab to the clinic	21
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration	21
Some like it hot: the potential role of hyperthermic intrathoracic chemotherapy in the multimodality treatment of pleural mesothelioma	21
A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA	20
The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer	20
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open- label phase 2 study (CLEAR)	20
Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study	20
Diagnostic accuracy and safety of electromagnetic navigation transthoracic needle biopsy under moderate sedation for the diagnosis of peripheral pulmonary lesions	19
A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy	19
Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database	19
Circulating tumor cell methylation profiles reveal the classification and evolution of non-small cell lung cancer	19
Treatment patterns and clinical outcomes of resectable central non-small cell lung cancer patients undergoing sleeve lobectomy: a large-scale, single-center, real-world study	18
A narrative review of the migration and invasion features of non-small cell lung cancer cells upon xenobiotic exposure: insights from in vitro studies	18
Identification of distinct tumor cell patterns with single-cell RNA sequencing integrating primary lung adenocarcinoma and brain metastasis tumor	18
Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer	18
Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study	18
Hyperthermic intrathoracic chemotherapy in overcoming tyrosine kinase inhibitor resistance in a patient with malignant pleural effusion: a case report	17
Optimizing long-term treatment with ALK inhibitors: balancing efficacy and safety	17
Advancements of ALK inhibition of non-small cell lung cancer: a literature review	17
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done	17
DNA methylation profiling in early lung adenocarcinoma to predict response to immunotherapy	17
International consensus on severe lung cancer—the first edition	17
Connecting the dots: (RANKL+) extracellular vesicle count in blood plasma in relation to bone metastases, skeletal related events and osimertinib treatment in patients with EGFR mutated non-small cell	17
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with con	17
Exploration of a novel prognostic model based on nomogram in non-small cell lung cancer patients with distant organ metastasis: implications for immunotherapy	16
How SOLID is the immune system’s response to the deadly duo of lung cancer and SARS-CoV-2?	16
Homologous recombination pathway gene variants identified by tumor-only sequencing assays in lung carcinoma patients	16
Causal effects of genetically determined metabolites on cancers included lung, breast, ovarian cancer, and glioma: a Mendelian randomization study	16
Follow-up regimen after lung cancer treatment: about the how and why	16
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer	16
Carinal resection and reconstruction: now and in the future	15
DLL3-targeted CAR T-cell therapy in pre-clinical models for small cell lung cancer: safety, efficacy, and challenges	15
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer	15
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged N	15
The long-term oncologic outcomes of robot-assisted bronchial single sleeve lobectomy for 104 consecutive patients with centrally located non-small cell lung cancer	15
Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies	15
Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions	15
Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer	15
Breast metastases from primary lung cancer: a retrospective case series on clinical, ultrasonographic, and immunohistochemical features	15
Lower respiratory tract microbiome is associated with checkpoint inhibitor pneumonitis in lung cancer patients	15
Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18	15
Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study	15

Another point of view for meta-analysis studies focused on protective inhaled corticosteroids and the risk of lung cancer	15
Development and validation of a dynamic survival nomogram for metastatic non-small cell lung cancer based on the SEER database and an external validation cohort	15
Evaluating three-dimensional lung reconstructions for thoracoscopic lung resections using open-source software: a pilot study	14
Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review	14
Will “Sun”-WUKONG, the monkey king, conquer EGFR exon 20 insertion mutation positive non-small cell lung cancer?	14
Health-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases	14
Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review	14
Patient-reported impact of symptoms in lung cancer (PRISM-LC)	14
Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer	14
Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 ≥50%	14
Spontaneous ventilation video-assisted thoracoscopic surgery for octogenarian non-small cell lung cancer patients: a non-inferiority study	14
LungPath: artificial intelligence-driven histologic pattern recognition for improved diagnosis of early-stage invasive lung adenocarcinoma	14
Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC	14
Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study	14
Preclinical evaluation of thin convex probe endobronchial ultrasound-guided transbronchial needle aspiration for intrapulmonary lesions	14
Single-cell and spatial transcriptomics reveal a potential role of ATF3 in brain metastasis of lung adenocarcinoma	14
Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally ad	13
Use of tumor cell lysate to develop peptide vaccine targeting cancer-testis antigens	13
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study	13
Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial	13
Enhancing the precision of auxiliary diagnosis for lung cancer through use of SHOX2 and RASSF1A methylation status in lung biopsy and lymph node biopsy specimens	13
Are polygenic risk scores ready for the cancer clinic?—a perspective	13
Immune-related osteoblastic bone alterations mimicking bone metastasis in a small-cell lung cancer patient treated with durvalumab: a case report	13
Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple ALK fusions treated with tyrosine kinase inhibitors	13
Cancer cachexia research: coming of age	13
Future lung cancer prediction using low-dose chest computed tomography	13
Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system	13
Editorial on: are we achieving ultimative limits of the minimally invasive thoracic surgery?	13
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study	13
First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic	13
PD-1 expression on tumor cells: a new target for cancer therapy	13
Editorial commentary: a journey towards least invasive thoracic surgery?	13
Dual immuno-oncology agents as neoadjuvant therapy for patients with resectable non-small cell lung cancer	12
Role of radiomics in predicting lung cancer spread through air spaces in a heterogeneous dataset	12
Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer	12
Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy	12
tsRNA-5001a promotes proliferation of lung adenocarcinoma cells and is associated with postoperative recurrence in lung adenocarcinoma patients	12
Lung cancer susceptibility beyond smoking history: opportunities and challenges	12
Clinical and prognostic significance of detecting CEA, EGFR, LunX, c-met and EpCAM mRNA-positive cells in the peripheral blood, tumor-draining blood and bone marrow of non-small cell lung cancer patie	12
Exploring the efficacy of artificial neural networks in predicting lung cancer recurrence: a retrospective study based on patient records	12
Clinical characteristics, surgical treatments, prognosis, and prognostic factors of primary tracheal cancer patients: 20-year data of the National Cancer Center, China	12
Risk stratification model for patients with stage I invasive lung adenocarcinoma based on clinical and pathological predictors	12
Radiotherapy as salvage therapy and an adjunct to immunotherapy: exploring local and abscopal mechanisms to overcome immunotherapy resistance: a narrative review	12
Preoperative computer tomography-guided indocyanine green injection is associated with successful localization of small pulmonary nodules	12
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups	12
Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and	12
Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study	11
Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow	11
Exosomal miR-182-5p is a potential diagnostic marker for malignant pleural effusion	11
Knowledge and beliefs about lung cancer screening among Black individuals at high risk: a qualitative approach	11
Cellular senescence and lung cancer prognosis	11
Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboring HER2 exon 19, p.L755P mutation: case report	11
Fibre-based fluorescence-lifetime imaging microscopy: a real-time biopsy guidance tool for suspected lung cancer	11
What do we know about the role of neoadjuvant targeted therapy in early-stage EGFR-mutant and ALK-fused non-small cell lung cancer?—a narrative review of the current literature	11
SMARCA4 deficiency: implications for non-small cell lung cancer and management strategies, with relevance to and distinctions from thoracic undifferentiated tumor	11
A prospective phase 2 study of expeditious EGFR genotyping and immediate therapeutic initiation through extracellular vesicles (EV)-based bronchoalveolar lavage fluid (BALF) liquid biopsy in advanced	11
Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials	11
False positivity in break apart fluorescence in-situ hybridization due to polyploidy	11
Age at first sexual intercourse, age at menarche, and age at menopause: a mendelian randomization study on lung cancer risk	11
Efficacy and safety of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in patients with extensive-stage small-cell lung cancer: a retrospective cohort study	11
Predictive value of the monocyte-to-high-density lipoprotein ratio in the prognosis of non-small cell lung cancer patients after surgery	11
Oncogene-addicted solid tumors and microbiome—lung cancer as a main character: a narrative review	11
Determinants of Aurora kinase B inhibitor sensitivity in small cell lung cancer	11
Penetrating the central nervous system sanctuary of KRAS, a target once thought “undruggable”	11
Lymph node dissection of station 8 improves the survival of T≤3 cmN0M0 lung adenocarcinoma patients	11
Altered carnitine transporter genes (SLC22A5, SLC22A16, SLC6A14) expression pattern among lung cancer patients	10
Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers	10
Fluorofenidone enhances cisplatin efficacy in non-small cell lung cancer: a novel approach to inhibiting cancer progression	10
Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence	10
Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: a narrative review	10
Epidermal growth factor receptor exon 20 insertion mutations: are we getting closer to solving the puzzle?	10
Predictive value of longitudinal systemic inflammatory markers for pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer	10
Construction and validation of deep learning model for cachexia in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors: a multicenter study	10
Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations	10
A multiethnic bidirectional Mendelian randomization study negates causal effects of C-reactive protein concentrations on lung cancer	10
The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy: a retrospective study	10
Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC)	10
Racial disparities in histological subtype, stage, tumor grade and cancer-specific survival in lung cancer	10
Identification of lysosomal genes associated with prognosis in lung adenocarcinoma	10
A prediction model integrated genomic alterations and immune signatures of tumor immune microenvironment for early recurrence of stage I NSCLC after curative resection	10

Learning curve for uniportal thoracoscopic pulmonary segmentectomy: how many procedures are required to acquire expertise?	10
Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer	9
Invasive mucinous adenocarcinoma harbored MET exon 14 skipping mutation: case report	9
Integrative genomic profiling reveals characteristics of lymph node metastasis in small cell lung cancer	9
Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients	9
Increased serum levels of KiSS1-derived peptides in non-small cell lung cancer patient liquid biopsies and biological relevance	9
The APPLE trial in the evolving landscape of ctDNA monitoring	9
Impact of lymph node dissection on cancer-specific survival in non-small cell lung cancer patients: a SEER database analysis	9
Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)	9
Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated n	9
STING facilitates the development of radiation-induced lung injury via regulating the PERK/eIF2α pathway	9
A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma	9
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review	9
Efficacy of neoadjuvant immunochemotherapy in the treatment of stage III non-small-cell lung cancer with cancer driver gene mutations	9
Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study	9
Residual tumor descriptors proposed by the International Association for the Study of Lung Cancer may not be applicable to stage I and ground-glass opacity-featured non-small cell lung cancer	9
Hybrid stenting with silicone Y stents and metallic stents in the management of severe malignant airway stenosis and fistulas	9
Osimertinib as a neoadjuvant therapy in resectable EGFR-mutant non-small cell lung cancer: a real-world, multicenter retrospective study	9
Systemic immune index predicts tumor-infiltrating lymphocyte intensity and immunotherapy response in small cell lung cancer	9
Biomarkers as a tool to reduce disparities in lung cancer screening and detection	9
Integrating radiomics and deep learning for enhanced prediction of high-grade patterns in stage IA lung adenocarcinoma	9
A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab	9
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22	9
BRAF RNA is prognostic and widely expressed in lung adenocarcinoma	9
DeepGR: a deep-learning prognostic model based on glycolytic radiomics for non-small cell lung cancer	9
Differential impact of intratumor heterogeneity (ITH) on survival outcomes in early-stage lung squamous and adenocarcinoma based on tumor mutational burden (TMB)	9
Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer	9
Fuel for thought: targeting metabolism in lung cancer	8
Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer	8
The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases	8
Predicting survival in small cell lung cancer patients undergoing various treatments: a machine learning approach	8
Comprehensive management of MET tyrosine kinase inhibitor-induced peripheral edema in patients with MET-altered non-small-cell lung cancer: a narrative review	8
Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives	8
Improved diagnostic accuracy with three lung tumor markers compared to six-marker panel	8
Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?—a narrative review	8
Augmented reality navigation-guided intraoperative pulmonary nodule localization: a pilot study	8
Adrenal crisis and acute exacerbation of interstitial lung disease after thymoma needle biopsy: a case report and literature review	8
Prognostic value of L4 lymph node dissection during video-assisted thoracoscopic surgery in patients with left-sided non-small cell lung cancer: a single-center, retrospective cohort study	8
Contribution of crosstalk of mesothelial and tumoral epithelial cells in pleural metastasis of lung cancer	8
Complete disease remission in a TP53 and KRAS co-mutated brain oligometastatic lung cancer patient after immuno-chemotherapy and surgical resection: a case report	8
PD-L1 expression in non-small cell lung carcinoma in Latin America: a systematic review and meta-analysis	8
Construction of a neutrophil extracellular trap formation-related gene model for predicting the survival of lung adenocarcinoma patients and their response to immunotherapy	8
Cerebrospinal fluid cytology for the diagnosis of lung cancer brain metastasis: a case report	8
Liquid biopsy in non-small cell lung cancer—current status and future outlook—a narrative review	8
Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis	8
Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients wit	8
The current state of carinal resection and role of minimally invasive techniques	8
Multidisciplinary international expert consensus on perioperative airway management	8
Construction and validation of a novel ferroptosis-related prognostic signature for lung adenocarcinoma	8
Comparative characteristics of small cell lung cancer and Ewing’s sarcoma: a narrative review	7
Development of a cuproptosis-related signature for prognosis prediction in lung adenocarcinoma based on WGCNA	7
A narrative review from gut to lungs: non-small cell lung cancer and the gastrointestinal microbiome	7
Immunotherapy in oncogene addicted non-small cell lung cancer	7
TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemorad	7
Clinical application of three-dimensional reconstruction in anatomical analysis of the right anterior, lateral, and posterior basal segments (RS8, RS9, and RS10) for RS9 segmentectomy	7
Patient-focused insights: how emotional distress shapes immunotherapy response in non-small cell lung cancer	7
Ion robotic bronchoscopy laser ablation and Da Vinci robotic segmentectomy for bilateral pulmonary nodules: a case report	7
Aurora kinase B inhibition in small-cell lung cancer: BCL-2 as a potential therapeutic biomarker and combination target	7
The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy	7
Primary resistance to ALK inhibitors in KLC1/ALK-rearranged pleural metastatic lung adenocarcinoma: a case report	7
Value of 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the differential diagnosis of sarcoidosis and lung cancer with lymph node metastasis: a retrospectiv	7
The strategy of non-intubated spontaneous ventilation anesthesia for upper tracheal surgery: a retrospective case series study	7
Association between changes in thioredoxin reductase and other peripheral blood biomarkers with response to PD-1 inhibitor-based combination immunotherapy in non-small cell lung cancer: a retrospectiv	7
Association of systemic therapy with survival among adults with advanced non-small cell lung cancer	7
EGFR exon 20 insertion mutation and MET exon 14 skipping mutation in non-small cell lung cancer: a scoping review in the Chinese population	7
KMT2C expression and DNA homologous recombination repair factors in lung cancers with a high-grade fetal adenocarcinoma component	7
A potential central nervous system niche for trastuzumab deruxtecan in patients with HER2-expressing non-small cell lung cancer	7
Recurrence prediction of lung adenocarcinoma using an immune gene expression and clinical data trained and validated support vector machine classifier	7
Deep learning model for predicting spread through air spaces of lung adenocarcinoma based on transfer learning mechanism	7
Shift in lung cancer stage at diagnosis during the COVID-19 pandemic in New York City	7
Genomic alterations dissection revealed MUC4 mutation as a potential driver in lung adenocarcinoma local recurrence	7
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study	7
Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer	7
Evaluation of the novel International Association for the Study of Lung Cancer grading system in adenocarcinoma with spread through air space	7
The time-to-surgery interval and its effect on pathological response after neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a retrospective cohort study	7
Review of the use of radiomics to assess the risk of recurrence in early-stage non-small cell lung cancer	7
Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma	7
EGFR inhibitors plus dabrafenib and trametinib in patients with EGFR-mutant lung cancer and resistance mediated by BRAFV600E mutation: a multi-center real-world experience in China	7
International expert consensus on immunotherapy for early-stage non-small cell lung cancer	7
The association between clinical parameters and resectability in stage III non-small cell lung cancer, and a combination of N2 lymph node burden and lung immune prognostic index score as a potential b	7
Molecular and immune characterization of Chinese early-stage non-squamous non-small cell lung cancer: a multi-omics cohort study	7
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)	6
Characteristics of the immune microenvironment and their clinical significance in lung adenocarcinoma patients with different ALK fusion variants	6
Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?	6
Expression of cytokines in pleural effusions and corresponding cell lines of small cell lung cancer	6
Predicting complication risks after sleeve lobectomy for non-small cell lung cancer	6
Methodological aspects of studies on survival after immunotherapy in stage IV non-small cell lung cancer	6
Unravelling the complexity of EGFR-mutated lung adenocarcinoma: a unique case report with histological transformations and co-alteration acquisition	6
ANKRD11 as a potential biomarker for brain metastasis from lung adenocarcinoma via cerebrospinal fluid liquid biopsy	6
Real-world biomarker testing patterns: clinical-pathological portrait of early and late non-small cell lung cancer in hub and spoke North Italian centers	6
Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation?	6
The utility and feasibility of three-dimensional reconstruction in surgical planning for multiple pulmonary nodules: a prospective self-controlled study	6
Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage	6
Radiomic signature accurately predicts the risk of metastatic dissemination in late-stage non-small cell lung cancer	6
Single cell RNA-seq and bulk RNA-seq analysis identifies MUC1 as a key gene for lung adenocarcinoma to neuroendocrine transformation	6